CHIKV VLP/unadjuvanted + CHIKV VLP/adjuvanted + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chikungunya Virus Infection
Conditions
Chikungunya Virus Infection
Trial Timeline
Apr 18, 2018 → Sep 21, 2020
NCT ID
NCT03483961About CHIKV VLP/unadjuvanted + CHIKV VLP/adjuvanted + Placebo
CHIKV VLP/unadjuvanted + CHIKV VLP/adjuvanted + Placebo is a phase 2 stage product being developed by Bavarian Nordic for Chikungunya Virus Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03483961. Target conditions include Chikungunya Virus Infection.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03483961 | Phase 2 | Completed |
Competing Products
20 competing products in Chikungunya Virus Infection